HLTRF.US HLS Therapeutics Inc

Healthcare Pharmaceuticals USA Stocks
2.60 USD
Close of Nov 14, 2026
2.46 3.47
Market cap
USD 80.4M
P/E
-
P/B
1.46x
ROE
-14.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HLTRF.US undervalued?

Graham number

The Graham number of HLS Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HLS Therapeutics Inc fundamental analysis

No fundamental analysis for HLS Therapeutics Inc yet.

HLS Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HLS Therapeutics Inc

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that a…

Full company profile